<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Novel therapeutic regimens containing <z:chebi fb="0" ids="35584">purine</z:chebi> analogs and monoclonal antibodies have led to significant improvement in the course of indolent <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> (LPD) </plain></SENT>
<SENT sid="1" pm="."><plain>Complete clinical and even molecular remissions have been achieved in an increasing proportion of patients </plain></SENT>
<SENT sid="2" pm="."><plain>In parallel to their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cytotoxic effect, these agents are inevitably associated with prolonged immunosuppression inherent to their mechanism of antilymphocytic activity </plain></SENT>
<SENT sid="3" pm="."><plain>Until now, attention has been paid mainly to <z:e sem="disease" ids="C0029118" disease_type="Disease or Syndrome" abbrv="">opportunistic infection</z:e> occurring as a result of the above drug-induced immunosuppression and less to other possible complications, such as <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> or <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in the immunocompromised host </plain></SENT>
<SENT sid="4" pm="."><plain>Here we briefly report nine patients with previously treated indolent LPD in whom the <z:hpo ids='HP_0003674'>onset</z:hpo> of large-cell transformation occurred during or shortly after the initiation of regimens containing these agents before transformation occurred </plain></SENT>
<SENT sid="5" pm="."><plain>One patient had received rituximab alone, three fludarabine-containing regimens and five received sequential regimens containing both agents </plain></SENT>
<SENT sid="6" pm="."><plain>This </plain></SENT>
</text></document>